Search

Your search keyword '"Schünemann, Holger J"' showing total 28 results
Start Over Author "Schünemann, Holger J" Publisher american thoracic society
28 results on '"Schünemann, Holger J"'

2. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline

Author

Raghu, Ganesh, primary, Rochwerg, Bram, additional, Zhang, Yuan, additional, Garcia, Carlos A. Cuello, additional, Azuma, Arata, additional, Behr, Juergen, additional, Brozek, Jan L., additional, Collard, Harold R., additional, Cunningham, William, additional, Homma, Sakae, additional, Johkoh, Takeshi, additional, Martinez, Fernando J., additional, Myers, Jeffrey, additional, Protzko, Shandra L., additional, Richeldi, Luca, additional, Rind, David, additional, Selman, Moisés, additional, Theodore, Arthur, additional, Wells, Athol U., additional, Hoogsteden, Henk, additional, and Schünemann, Holger J., additional

Published
2015
Full Text
View/download PDF

3. Moving from Evidence to Developing Recommendations in Guidelines

Author

Schünemann, Holger J., primary, Oxman, Andy D., additional, Akl, Elie A., additional, Brozek, Jan L., additional, Montori, Victor M., additional, Heffner, John, additional, Hill, Suzanne, additional, Woodhead, Mark, additional, Campos-Outcalt, Doug, additional, Alderson, Phil, additional, Woitalla, Thomas, additional, Puhan, Milo A., additional, Falck-Ytter, Yngve, additional, Bousquet, Jean, additional, and Guyatt, Gordon, additional

Published
2012
Full Text
View/download PDF

5. Guideline Group Composition and Group Processes

Author

Kunz, Regina, primary, Fretheim, Atle, additional, Cluzeau, Françoise, additional, Wilt, Timothy J., additional, Qaseem, Amir, additional, Lelgemann, Monika, additional, Kelson, Marcia, additional, Guyatt, Gordon, additional, and Schünemann, Holger J., additional

Published
2012
Full Text
View/download PDF

6. Reporting and Publishing Guidelines

Author

Wilson, Kevin C., primary, Irwin, Richard S., additional, File, Thomas M., additional, Schünemann, Holger J., additional, Guyatt, Gordon H., additional, and Rabe, Klaus F., additional

Published
2012
Full Text
View/download PDF

7. Disseminating and Implementing Guidelines

Author

Grimshaw, Jeremy M., primary, Schünemann, Holger J., additional, Burgers, Jako, additional, Cruz, Alvaro A., additional, Heffner, John, additional, Metersky, Mark, additional, and Cook, Deborah, additional

Published
2012
Full Text
View/download PDF

9. Synthesis, Grading, and Presentation of Evidence in Guidelines

Author

Guyatt, Gordon, primary, Akl, Elie A., additional, Oxman, Andy, additional, Wilson, Kevin, additional, Puhan, Milo A., additional, Wilt, Timothy, additional, Gutterman, David, additional, Woodhead, Mark, additional, Antman, Elliott M., additional, and Schünemann, Holger J., additional

Published
2012
Full Text
View/download PDF

10. Stakeholder Involvement: How to Do It Right

Author

Cluzeau, Françoise, primary, Wedzicha, Jadwiga A., additional, Kelson, Marcia, additional, Corn, Judy, additional, Kunz, Regina, additional, Walsh, John, additional, and Schünemann, Holger J., additional

Published
2012
Full Text
View/download PDF

12. Guideline Funding and Conflicts of Interest

Author

Boyd, Elizabeth A., primary, Akl, Elie A., additional, Baumann, Michael, additional, Curtis, J. Randall, additional, Field, Marilyn J., additional, Jaeschke, Roman, additional, Osborne, Molly, additional, and Schünemann, Holger J., additional

Published
2012
Full Text
View/download PDF

17. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

Author

Raghu, Ganesh, primary, Collard, Harold R., additional, Egan, Jim J., additional, Martinez, Fernando J., additional, Behr, Juergen, additional, Brown, Kevin K., additional, Colby, Thomas V., additional, Cordier, Jean-François, additional, Flaherty, Kevin R., additional, Lasky, Joseph A., additional, Lynch, David A., additional, Ryu, Jay H., additional, Swigris, Jeffrey J., additional, Wells, Athol U., additional, Ancochea, Julio, additional, Bouros, Demosthenes, additional, Carvalho, Carlos, additional, Costabel, Ulrich, additional, Ebina, Masahito, additional, Hansell, David M., additional, Johkoh, Takeshi, additional, Kim, Dong Soon, additional, King, Talmadge E., additional, Kondoh, Yasuhiro, additional, Myers, Jeffrey, additional, Müller, Nestor L., additional, Nicholson, Andrew G., additional, Richeldi, Luca, additional, Selman, Moisés, additional, Dudden, Rosalind F., additional, Griss, Barbara S., additional, Protzko, Shandra L., additional, and Schünemann, Holger J., additional

Published
2011
Full Text
View/download PDF

20. An Official ATS Statement: Grading the Quality of Evidence and Strength of Recommendations in ATS Guidelines and Recommendations

Author

Schünemann, Holger J., primary, Jaeschke, Roman, additional, Cook, Deborah J., additional, Bria, William F., additional, El-Solh, Ali A., additional, Ernst, Armin, additional, Fahy, Bonnie F., additional, Gould, Michael K., additional, Horan, Kathleen L., additional, Krishnan, Jerry A., additional, Manthous, Constantine A., additional, Maurer, Janet R., additional, McNicholas, Walter T., additional, Oxman, Andrew D., additional, Rubenfeld, Gordon, additional, Turino, Gerard M., additional, and Guyatt, Gordon, additional

Published
2006
Full Text
View/download PDF

27. Moving from Evidence to Developing Recommendations in Guidelines

Author

Jan Brozek, Andrew D Oxman, Gordon H. Guyatt, Suzanne Hill, Holger J. Schünemann, Thomas Woitalla, Jean Bousquet, Milo A. Puhan, Elie A. Akl, Doug Campos-Outcalt, Yngve Falck-Ytter, Mark Woodhead, John E. Heffner, Phil Alderson, Victor M. Montori, University of Zurich, and Schünemann, Holger J

Subjects
Pulmonary and Respiratory Medicine, Biomedical Research, Evidence-Based Medicine, business.industry, MEDLINE, Disease Management, Pulmonary disease, 610 Medicine & health, Guideline, Public relations, Pulmonary Disease, Chronic Obstructive, Research Design, 2740 Pulmonary and Respiratory Medicine, Practice Guidelines as Topic, Health care, Humans, Medicine, Professional association, Guideline development, 10029 Clinic and Policlinic for Internal Medicine, Disease management (health), Policy Making, business, Research evidence
Abstract

Professional societies, like many other organizations around the world, have recognized the need to use more rigorous processes to ensure that healthcare recommendations are informed by the best available research evidence. This is the 11th of a series of 14 articles that methodologists and researchers from around the world prepared to advise guideline developers for respiratory and other diseases on how to achieve this goal. For this article, we developed five key questions and updated a review of the literature on moving from evidence to recommendations.We addressed the following specific questions.What is the strength of a recommendation and what determines the strength? What are the implications of strong and weak recommendations for patients, clinicians, and policy makers? Should guideline panels make recommendations in the face of very low-quality evidence? Under which circumstances should guideline panels make research recommendations? How should recommendations be formulated and presented? We searched PubMed and other databases of methodological studies for existing systematic reviews and relevant methodological research. We did not conduct systematic reviews ourselves. Our conclusions are based on available evidence, consideration of what guideline developers are doing, and pre- and postworkshop discussions.The strength of a recommendation reflects the extent to which guideline developers can, across the range of patients for whom the recommendations are intended, be confident that the desirable effects of following the recommendation outweigh the undesirable effects. Four factors influence the strength of a recommendation: the quality of evidence supporting the recommendation, the balance between desirable and undesirable effects, the uncertainty or variability of patient values and preferences, and costs. Strong and weak (also called "conditional") recommendations have distinct implications for patients, clinicians, and policy makers. Adherence to strong recommendations or, in the case of weak (conditional) recommendations, documentation of discussion or shared decision making with a patient, might be used as quality measures or performance indicators. Clinicians desire guidance regardless of the quality of the underlying evidence. Very low-quality evidence should ideally result in either appropriately labeled recommendations (i.e., as based on very low-quality evidence) or a statement that the guideline panel did not reach consensus on the recommendation due to the lack of confidence in the effect estimates. However, guideline panels often have more resources, time, and information than practicing clinicians. Therefore, they may be in a position to use their best judgments to make recommendations even when there is very low-quality evidence, although some guideline developers disagree with this approach and prefer a general approach of not making recommendations in the face of very low-quality evidence. Guideline panels should consider making research recommendations when there is important uncertainty about the desirable and undesirable effects of an intervention, further research could reduce that uncertainty, and the potential benefits and savings of reducing the uncertainty outweigh the potential harms of not making the research recommendation. Recommendations for additional research should be as precise and specific as possible.

Published
2012
Full Text
View/download PDF

28. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis.

Author

Jaeschke R, O'Byrne PM, Mejza F, Nair P, Lesniak W, Brozek J, Thabane L, Cheng J, Schünemann HJ, Sears MR, and Guyatt G

Subjects
Administration, Inhalation, Drug Interactions, Drug Therapy, Combination, Humans, Randomized Controlled Trials as Topic, Adrenal Cortex Hormones administration & dosage, Adrenergic beta-Antagonists adverse effects, Asthma drug therapy
Abstract

Rationale: Inhaled long-acting beta-agonists (LABAs), when used as monotherapy in asthma, may increase asthma-related hospitalizations, life threatening events requiring intubation/mechanical ventilation, and asthma-related deaths, but concomitant use of inhaled corticosteroids (ICS) may modify this effect., Objectives: To determine the safety of long-acting beta-agonists among patients with asthma using corticosteroids., Methods: We conducted a systematic review and metaanalysis of parallel-group, blinded, randomized, controlled trials with at least 12 weeks of treatment addressing the impact of LABA on asthma-related and total morbidity and mortality in patients concomitantly using ICS. We searched MEDLINE, EMBASE, ACPJC, and Cochrane (Central) databases, and contacted authors and sponsors., Measurements and Main Results: We used a random effects model to pool results from different studies as odds ratios (ORs) (95% confidence interval [CI]) (OR < 1.0 favors LABA). The search yielded 62 relevant studies included in this analysis. Among over 29,000 participants (15,710 taking LABA, with over 8,000 patient-years observed in the LABA groups), there were three asthma-related deaths and two asthma-related, nonfatal intubations (all in LABA groups;

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results